- Home
- ULY vs MYNZ Comparison
ULY vs MYNZ Comparison
Compare ULY & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULY
- MYNZ
- Stock Information
- Founded
- ULY 2013
- MYNZ 2021
- Country
- ULY United States
- MYNZ Germany
- Employees
- ULY N/A
- MYNZ N/A
- Industry
- ULY
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- ULY
- MYNZ Health Care
- Exchange
- ULY Nasdaq
- MYNZ Nasdaq
- Market Cap
- ULY 7.1M
- MYNZ 7.9M
- IPO Year
- ULY N/A
- MYNZ 2021
- Fundamental
- Price
- ULY $5.13
- MYNZ $1.77
- Analyst Decision
- ULY Strong Buy
- MYNZ Buy
- Analyst Count
- ULY 2
- MYNZ 2
- Target Price
- ULY $11.50
- MYNZ $14.00
- AVG Volume (30 Days)
- ULY 28.4K
- MYNZ 180.5K
- Earning Date
- ULY 08-12-2025
- MYNZ 08-26-2025
- Dividend Yield
- ULY N/A
- MYNZ N/A
- EPS Growth
- ULY N/A
- MYNZ N/A
- EPS
- ULY N/A
- MYNZ N/A
- Revenue
- ULY $131,235,000.00
- MYNZ $893,991.00
- Revenue This Year
- ULY N/A
- MYNZ $26.06
- Revenue Next Year
- ULY $21.54
- MYNZ $4.97
- P/E Ratio
- ULY N/A
- MYNZ N/A
- Revenue Growth
- ULY N/A
- MYNZ N/A
- 52 Week Low
- ULY $2.99
- MYNZ $1.30
- 52 Week High
- ULY $17.99
- MYNZ $18.40
- Technical
- Relative Strength Index (RSI)
- ULY 43.88
- MYNZ 53.56
- Support Level
- ULY $4.77
- MYNZ $1.41
- Resistance Level
- ULY $5.74
- MYNZ $1.76
- Average True Range (ATR)
- ULY 0.50
- MYNZ 0.16
- MACD
- ULY 0.03
- MYNZ 0.02
- Stochastic Oscillator
- ULY 59.06
- MYNZ 68.12
About ULY Urgent.ly Inc.
Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.